Radiopharmaceutical Manufacturing Market Size to Hit USD 13.79 Billion by 2035

Radiopharmaceuticals are gaining momentum with more regulatory approvals and promising clinical results in cancer therapy and precision diagnostics. This is expected to drive strong market growth over the next nine years. Ongoing improvements in isotope production, chelator technology, and precision diagnostics will help create safer and more effective treatments. Companies in this space are also partnering with big pharmaceutical and biotech firms to solve challenges like supply chain logistics, short isotope half-lives, and targeted alpha therapy delivery.

According to Roots Analysis, the Radiopharmaceutical Manufacturing Market (3rd Edition) was valued at USD 6.61 billion in 2026 and likely to hit USD 13.79 billion by 2035, growing at a CAGR of 8.5 % during the forecast period till 2035.

Key Report Takeaways

Given the rising cancer incidence and isotope supply constraints, players are expanding manufacturing to produce advanced radiopharmaceuticals for diagnosis and therapeutics purpose

More than 120 industry players are currently manufacturing radiopharmaceuticals, spanning a wide range of diagnostic and therapeutic applications across multiple indications

Close to 70% of the players are engaged in the manufacturing of both diagnostic and therapeutic radiopharmaceuticals; majority (35%) of these players are manufacturing radiopharmaceuticals across all scales

The non-industry radiopharmaceutical manufacturers have been assessed based on several relevant parameters in order to evaluate their capabilities in this domain

Several non-industry (established as well as startups) in this domain claim to have necessary capabilities to manufacture radiopharmaceuticals; majority (~45%) of these firms are based in North America

Most (98%) of the organizations are manufacturing radiopharmaceuticals for the diagnostic application area; close to 65% of the beta emitter manufacturing organizations are engaged in the manufacturing of Lutetium-177

Due to the rising demand for radiopharmaceuticals, there has been an increase in partnership activity; supply agreements (~30%) emerged as the most common type of partnership model in this domain

KOLs across the globe have shared their insights on market evolution, shifting dynamics, emerging trends, and high-impact opportunities shaping the future growth in radiopharmaceutical manufacturing market

Given the rising prevalence of cancer, increasing adoption of radiopharmaceutical therapies, and research efforts, this domain is expected to witness significant growth in the coming future

The radiopharmaceutical manufacturing market is likely to grow at an annualized rate (CAGR) of 8.5%, till 2035; notably, the diagnostic radiopharmaceuticals is anticipated to capture the majority share in the market by 2035

Currently, majority of the market share is captured by the genetic disorders sub-segment; a substantial market share is expected to be captured by North America, by 2035

Competitive Landscape of Radiopharmaceutical Manufacturing Market

The radiopharmaceutical manufacturing market landscape is highly fragmented, with the presence of very large, large, mid-sized and small companies offering diverse radiopharmaceuticals in the industry. These companies possess the required expertise to develop and commercialize radiopharmaceuticals across various geographical regions. Notably, more than 35% of the industry-players and close to 45% of non-industry players are engaged in this domain are based in North America.

Radiopharmaceutical Manufacturing Market Regional Outlook

Based on the geographical regions, the radiopharmaceutical manufacturing market can be segmented into four major regions, including North America, Europe, Asia-Pacific, Latin America, and Middle East and North Africa. Led by the US, North America is anticipated to capture the majority share in the radiopharmaceutical manufacturing market in 2026. Asia-Pacific is accounted to be the fastest-growing segment of the market. The growth of the radiopharmaceuticals in this region is primarily driven by growing geriatric population, rising incidences of cancer and cardiovascular diseases and advancements in medical imaging technologies in this region.

Radiopharmaceutical manufacturing market Key Players
Examples of key companies engaged in radiopharmaceutical manufacturing market (which have also been profiled in this market report; the complete list of companies is available in the full report) include:

BAMF Health
Cardinal Health
DuChemBio
Eckert & Ziegler
Evergreen Theragnostics
Isotopia Molecular Imaging
PharmaLogic
Primo Biotechnology
RadioMedix
SpectronRx

Read More: https://www.rootsanalysis.com/reports/nuclear-medicine-and-radiopharmaceuitcals-manufacturing.html